| INTRODUCTION
Extracellular vesicles (EV) are non-cellular vesicles with a phospholipid membrane derived from parental cells that exist in body fluids. EV are categorized into exosomes, microvesicles or microparticles (MV/MP), and apoptotic bodies, according to different biogenesis (György et al., 2011; Raposo & Stoorvogel, 2013) . Exosomes released from multivesicular bodies have been studied extensively because they contain various cellular proteins and nucleic acids such as miRNAs and play a role in intercellular communication (Squadrito et al., 2014) . MV/MP are produced by budding from the cell membrane, either spontaneously or in response to stimuli. So, the detection of MV/MP in the circulation may be useful for monitoring various diseases or for detecting acute change in disease states. Apoptotic bodies are products of apoptosis. The disintegration of cell membrane results in an exposure of phosphatidylserine present in the cytoplasmic leaflet that triggers phagocytosis by macrophages under physiological conditions (Segawa & Nagata, 2015) . When anticancer therapy is effective, production of apoptotic bodies by dying tumor cells can exceed the scavenging capacity of macrophages and circulating EV may be a useful marker of the response to treatment. Both apoptotic bodies and MV/MP retain components of surface antigens from the parent cells.
In addition to analysis of miRNA in EV, it has been proposed that quantification of circulating EV may be useful (Lucchetti, Fattorossi, & Sgambato, 2018; Shantsila, MontoroGarcia, & Lip, 2014; Welsh, Holloway, Wilkinson, & Englyst, 2017) . The relevance of circulating EV to various diseases has been investigated (refs. in Nomura, 2017) and several techniques for detecting these vesicles have been developed (Erdbrügger & Lannigan, 2016; Szatanek et al., 2017) , but the measurement has not yet been standardized. Conventional flow cytometry (FCM) is used most widely for detecting EV in clinical studies (Vozel, Uršič, Krek, Štukelj, & Kralj-Iglič, 2017) . While it allows high-throughput analysis, standard FCM does not achieve adequate resolution of particles in the submicron range (Erdbrügger et al., 2014) . Improvements to FCM-based strategies (Arraud, Gounou, Linares, & Brisson, 2015; Inglis et al., 2015) have been proposed, and specialized FCM analysers suitable for smaller particles are also being developed (Kibria et al., 2016; Morales-Kastresana et al., 2017) .
Another issue related to standard FCM-based assessment of circulating EV is that washing is not usually performed to remove excess antibodies after staining EV, so that nonspecific binding to non-target vesicles often leads to high background fluorescence. In addition, the fluorescence intensity of EV with low expression of the target antigen is often around the background noise level. Immunomagnetic separation of EV is one solution to these problems, allowing target EV to be easily purified by washing in a microtube or ELISA plate. However, the sensitivity for EV with low antigen expression will remain limited as long as immunofluorescence method is used for the detection.
EpCAM (epithelial cell adhesion molecule) is a transmembrane protein that is often over-expressed by epithelial cancers. Although its role in tumorigenesis is not fully understood, EpCAM has long been utilized for the detection of circulating tumor cells (CTC; Miller, Doyle, & Terstappen, 2010) and as a guide during surgery (van Driel et al., 2016; Winter, Nagtegaal, van krieken, & Litvinov, 2003) . Recently, EpCAM was also employed for the detection of EV released by malignant tumors (Willms et al., 2016) . Here, we describe quantitative detection of EpCAM-positive EV by combining immunomagnetic separation (IMS) of EpCAM-bearing EV with phospholipid staining (PS) of the separated vesicles (IMS-PS method). In the present study, we examined the feasibility of this method and compared it with conventional immunofluorescence. Several modifications were made during the development of the IMS-PS method to obtain stable and reproducible results, with the latest method achieving sensitive detection of EpCAM-positive EV prepared from the culture supernatants of cancer cell lines. Accurate quantification of cancer EV spiked into blood plasma from healthy volunteers was also demonstrated.
| RESULTS

| Preparation of EpCAM-positive EV from cultured cells and detection by immunofluorescence with an anti-EpCAM mAb
The detection of EV in body fluids has been made using FCM-based immunofluorescence to a surface antigen of interest. We describe here that the conventional immunofluorescence method is applicable for a detection of disease-associated EV, but would be difficult to quantitate them.
We prepared EpCAM-positive EV from cell culture supernatants as model EV for epithelial tumors. Most cultured cell lines derived from epithelial tumors express EpCAM surface antigen. Two human cancer cell lines were selected, which were OVCAR3 (ovarian cancer) with high EpCAM expression and A431 (squamous cell carcinoma) with low EpCAM expression. A mouse cancer cell line Colon-26 (colorectal cancer) was used for negative (nonhuman) control. After growing cells to the exponential phase (60%-80% confluence) in regular culture medium, it was exchanged for fresh medium (filtered through a membrane with 0.2 µm pores). Serum starvation and other stimuli have been reported to provoke the release of EV (Bernimoulin et al., 2009; Sun et al., 2014 ), but we investigated EV shed spontaneously by healthy cells to avoid the influence of apoptosis. The culture was continued for another 24 hr and EV were collected from the culture medium by centrifugation at 20 000x g, after which the EV pellet was resuspended in PBS with 2 mM EDTA (PBSE) for examination.
To obtain an appropriate light scattergram (forward scatter-side scatter: FS-SS) for FCM, the detector voltage was set using EV in PBSE (OVCAR3 EV and A431 EV) and the size gate [S] was set to include particles ranging from 0.5 to 2 μm in size (Supporting Information Figure S1 ). As a result, approximately 50%-70% of total ungated events [T] were included in the size gate [S] .
FCM histograms clearly separated EpCAM-positive and EpCAM-negative "parental cells" (Figure 1a ). However, EV were expected to show much lower fluorescence intensity than their parental cells because membrane surface antigen expression depends on the square of the diameter of a particle (Figure 1b) . So, the detector voltage had to be increased to obtain appropriate histograms for EV. We utilized a custom-made anti-human EpCAM mAb (KIJY1N: Supporting Information Figure S2 ), in order to adjust the amount added and to select better fluorescent dye for conjugation. Histograms of EV of each cell line are shown in Figure 1c . By increasing the detector voltage, we obtained reasonable histograms of both A431 EV and Genes to Cells TAKAO eT Al.
OVCAR3 EV. However, a false peak with a relatively high intensity appeared when Colon-26 EV (negative control) were examined. To exclude nonspecific adsorption of the mAb, centrifugal washing was repeated until the fluorescence of Colon-26 EV reached a basal level on fluorescent ELISA (Figure 1d) . Then, the EV were re-analysed by FCM (Figure 1e ). Under these conditions, the histograms of A431 EV and OVCAR3 EV showed peaks comparable to those of the parental cells (Figure 1e vs. 1A). The histograms also revealed that approximately 50% of A431 or OVCAR3 EV were positive for EpCAM (> 10e0), whereas the remaining 50% were negative (red-dashed line).
Although the false peak in Colon-26 EV samples was abolished after washing, there was still a shoulder and a strong tail toward the high-intensity region in FL4. This tail in the histogram meant that arbitrary determination of the cutoff value was required, but an ideal value was difficult to set. For example, if the cutoff value of fluorescence intensity was set at 5 x 10e1 so that all Colon-26 EV events were negative (blue-dashed line in Figure 1e) , most of the EpCAM-positive events for A431 EV and about a half of those for OVCAR3 EV would be lost. Accordingly, the signal of interest might be masked if the target EV were rare or showed low surface antigen expression. In addition, high-speed centrifugal washing is an exceptional process to this experiment and not practical in clinical tests. The strong centrifugal force to plasma may cause undesirable effects. Therefore, immunofluorescence seemed to have limitations as a method for quantifying EV.
| Immunomagnetic separation of EV and phospholipid staining
We next examined a method for positive separation of EV by using the MACS manual system. The supplier suggested that UltraPure bead were suitable for separating cells from crude samples, with Anti-Biotin MicroBeads UltraPure (which bind only to biotinylated complexes) being a better choice than Streptavidin MicroBeads (which bind to both free and conjugated biotin). Therefore, we created biotinylated KIJY1N mAb and coated Anti-Biotin MicroBeads UltraPure microbeads with it (UltraPure-KIJY1N) for use in separating EpCAM-positive EV. After the immunoreaction, the sample was applied to the MACS MS Column set in the magnetic field. Unbound EV and impurities were washed away by gravity flow as is done with open column chromatography.
During the washing procedure, the MS Column was filled with a dye solution to stain the phospholipid bilayers of trapped EV. We tested several lipidstaining dyes and selected Polaric TM -500c6F (Maishi et al., 2013; Tanaka et al., 2017) . This dye shows a large Stokes shift after excitation at 488 nm that allows multichannel analysis, which turns out to be advantageous for discriminating the target signal from autofluorescence as described below.
As a model of pure vesicles, synthetic liposomes (1,2-dimyristoyl-sn-glycerol-3-phosphorylcholine; DMPC liposomes) were created and stained with Polaric-500c6F. Then, the detector voltages for FL1 (505-545 nm) and FL2 (555-595 nm) were adjusted to give a linear diagonal FL2-FL1 F I G U R E 2 Strategy for setting the Polaric-500c6F-positive gate [P] . (a) Synthetic liposomes made from DMPC were stained with Polaric-500c6F dye. The detector voltages of FL1 and FL2 were adjusted so that the FL2-FL1 plot was a diagonal line. The dashed gate is an arbitrary region that contains the major population of dye-stained DMPC liposomes (left panel). Positively separated dye-stained OVCAR3 EV are shown (panel, EV-sep.) . Unstained concentrated OVCAR3 EV (without MACS) were used to detect vesicle-derived autofluorescence (panel, conc. EV). Unstained and unfiltered FBS (panel, FBS) contained fluorescent particles, which were probably protein aggregates and bovine EV. These autofluorescence events were present in the FL1> FL2 region, indicated by red-dashed lines. (b) FL2-FL1 scattergrams (enlarged) of plasma samples from healthy volunteers (V1 and V2), showing the total number of ungated events [T] . The Polaric-positive gate [P] was set at the conjunction of the cross-gate area (FL1 and FL2, >10e0) and the diagonal polygon gate. No events were recorded in the gate with both plasma samples. This FCM method measured the number of events in 3.37 µl of plasma Genes to Cells TAKAO eT Al.
plot (Figure 2a, DMPC) . The gate was set as shown by the dashed rectangle in Figure 2a . A similar plot was obtained by immunomagnetic separation of OVCAR3 EV (Figure 2a , EV-sep.), but some events were noted in the FL1>FL2 region (red-dashed oval). To investigate the source of events appearing in this region, concentrated EV without staining were measured and the results indicated that these events were autofluorescence of OVCAR3 EV (Figure 2a , conc. EV). Events were also detected in the FL1>FL2 region when unfiltered FBS was examined, which were probably derived from protein aggregates and bovine EV (Figure 2a, FBS) . These results indicated that biological molecules (including lipids and proteins) have some autofluorescence, but such signals can be separated from EV by using the Polaric dye.
In the FL2-FL1 plot, we defined the Polaric-positive gate [P] as follows. Plasma samples from two healthy volunteers were measured and a cross-gate was set to locate noise signals below 10e0. The cross-gate was overlaid on a polygonal gate from the scattergram obtained with dye-stained DMPC liposomes. Then, the gate [P] was set at the conjunction between the FL2>10e0, FL1>10e0 region and the polygonal gate (Figure 2b) 
| Reduction in nonspecific binding between microbeads ultrapure and non-target EV in plasma
Although there was less nonspecific binding (NSB) to MicroBeads UltraPure than to MACS MicroBeads, the bead were developed for separation of cells rather than subcellular particles such as EV. To evaluate NSB between microbeads and EV in plasma, uncoated MicroBeads UltraPure were incubated with plasma from a healthy volunteer that showed approximately 40 thousand events per measurement ([T] in Figure 3a) . As a result, binding was noted between the MicroBeads UltraPure and various particles in plasma. Figure 3b (untreated) reveals that pseudo-separated particles were stained by Polaric dye (upper left), indicating that the UltraPure bead adsorbed a non-negligible amount of non-target EV from plasma.
After several attempts, we found that pretreatment of the bead with conventional blocking agents overcame this problem. Overnight incubation of the bead with 5% skim milk (SM; middle panel) or ECL-blocking agent (ECL; lower panel) significantly reduced NSB events in the [S]&[P] gate. As summarized in Figure 3c , more than 10-fold reduction in events was achieved by such treatment. We also found that the number of microbeads added to the sample was correlated with the NSB count (Figure 3d) , suggesting that addition of fewer bead could improve the signal-to-noise ratio if target EV were expected to be rare.
The left panels in Figure 3b show ungated FL2-FL1 plots with a total number of events [T] . In separate experiments performed without plasma, we confirmed that 50 nm MicroBeads accounted for approximately 1,500 events per measurement and the bead were not stained by the dye, suggesting that the presence of free MicroBeads in the FCM sample solution little affected the number of events in [S]&[P] gate. Figure 4a outlines the development of our strategy to overcome the problem that FCM histograms obtained with conventional immunofluorescence staining contained a mixture of signals from the target antigen, non-target proteins and nonspecific adsorption. After switching from immunofluorescence to the IMS-PS method, we found that it was easy to wash the microbeads, but some NSB remained (IMS-PS in Figure 4a ). Subsequently, we found that pretreatment of the bead with a blocking agent markedly reduced NSB, as shown in Figure 3c .
| Quantitation of EV from cultured cells
EV derived from cultured cancer cells were examined to ascertain whether the improved method could provide quantitative data. An appropriate bead amount in the immunoreaction was determined by varying the solution volume of the ECL-pretreated UltraPure-KIJY1N bead to a given amount of EV. In separate experiments, we prepared A431 EV which indicated an average count of 273.4 per measurement (SD = 54.9, n = 5). As shown in Figure 4b , the bead amount of 2.3 µl or more gave a sufficient detection efficiency, whereas the efficiency declined by 60% or 10% when the volume of the bead was reduced to 1.5 µl or 0.8 µl, respectively. As a compromised point between lower NSB (Figure 3d ) and sufficient detection efficiency (Figure 4b ), we mixed 2.5 µl of the bead with EV sample equivalent to 20-60 µl of culture supernatant in a final reaction volume of 62.5 µl (Figure 4c ).
The count of EpCAM-negative EV from Colon-26 cells did not vary as the EV sample volume was changed. In contrast, there was a linear relation between sample volume and the EV count with samples of EV from both A431 cells and OVCAR3 cells. Therefore, the IMS-PS method was able to quantify EV regardless of the level of surface antigen expression. FCM scattergrams obtained by reacting EV samples of 60 µl with UltraPure-KIJY1N are shown in Figure 4d . Figure 4e is an image of EV selected by the bead and enumerated in [S]&[P].
While we used 500 µl of EV to obtain an appropriate histogram with immunofluorescence staining (Figure 1) , the IMS-PS method could be performed with a smaller volume (20-60 µl) because the cumulative FCM histogram is not necessary.
| Spiking Experiments
To evaluate the detection efficiency of our method, we spiked EpCAM-poor EV derived from A431 cells into the plasma of a healthy volunteer ( Figure 5 ). The reaction mixture (50 µl) contained the following: 30 µl PBSE, 5µl of UltraPure-KIJY1N pretreated with blocking agent, 10 µl of plasma and 5 µl of A431 EV dissolved in 0.1 ml of PBSE (a 10-fold higher concentration than in the sample used to obtain data shown in Figure 4b ).
Using bovine serum as a mimic of human plasma, the number of EV spiked was estimated to be approximately 200 events per measurement ( Figure 5 , FBS column in the bar graphs). Spiking tests were carried out in triplicate with separate immunoreactions and MACS operations, revealing reasonable recovery of EV from spiked plasma (red bars). Raw FCM charts for FBS and plasma (Experiment 1) in Figure 5b are provided in the Supporting Information ( Figure S3 ).
These data demonstrated that the IMS-PS method could quantify EpCAM-positive EV in plasma. The spiking test was performed as an indicator of the situation when measuring plasma from patients with epithelial cancer, and the results suggested that our strategy could improve the detection of EV with low EpCAM positivity in clinical specimens, which would otherwise be hidden by the negative control or noise when using FCM with immunofluorescence. Toward clinical tests, we plan to portion a plasma specimen into two samples and perform IMS-PS with anti-EpCAM bead for disease detection and with control-IgG bead for reference.
| DISCUSSION
| Features of the IMS-PS method
In contrast to immunofluorescence, the IMS-PS method allows removal of excess dye, impurities and non-target plasma EV by mild washing. The key concept of this method is the detection of EV by staining the phospholipid bilayer instead of direct immunostaining of surface antigens.
The method is quite simple. First, EV of interest are immobilized to the solid phase while non-target plasma constituents are washed away. Nanosize MACS MicroBeads were used because these bead have little influence on the FCM scattergram in the target size range (0.5-2 µm). We previously investigated the detection of CTC by using MACS MicroBeads-CD326 (Takao & Takeda, 2011) . We found that the MACS system worked well with samples after lysis of red blood cells, whereas whole blood samples were often adsorbed to the MS Column. In the present study, we used plasma samples and MicroBeads UltraPure and did not found any problems with clogging of the MS Column. Since there is a limited selection of commercially available MicroBeads-antibody conjugates, we created a biotinylated mAb (KIJY1N) and used it to coat Anti-Biotin MicroBeads UltraPure. We also switched the staining target from surface antigens to the abundant phospholipid bilayer of EV, which resulted in sufficient signal intensity for the detection of microparticles with very low levels of antigen expression. We found that Polaric-500c6F was the best dye among tested for staining the phospholipid of EV with regard to brightness, water-solubility and keeping intactness (i.e., FS-SS scattergrams of EV were not affected by staining). Another advantage is that the combination of a biotinylated mAb with Anti-Biotin MicroBeads UltraPure is flexible, so different tumor markers can be targeted by changing the antibody.
To investigate the reproducibility of this method, spiking experiments were performed with another standard FCM analyser (BD FACSCanto II). These experiments demonstrated a linear relation between the amount of A431 EV spiked into healthy volunteer plasma and the number of A431 EV detected, as shown in the Supporting Information (Figure S4 ).
| Implication of measuring EV
CTC have shown limited value as a biomarker for predicting the prognosis of cancer. Using the CellSEARCH CTC system, the detection of more than three or five CTC in a blood sample of 7.5 ml is defined as positive (Miller et al., 2010) . This system measures viable CTC, while dead cells and fragments are disregarded. Among the immunomagnetically separated EpCAM-positive particles, only a few percent seem to be selected as "live" CTC (Swaby & Cristofanilli, 2011) . Instead of counting presumed viable CTC, we wanted to develop a method for quantifying EV originated from primary tumor in the blood that could be of assistance for diagnosis and evaluating the response to therapy (Aubertin et al., 2016; Wu, Xing, & Watabe, 2017) , using a standard FCM analyser. The present IMS-PS method could be applicable to the investigation of both cancer markers and other non-cancer markers (Campello, Spiezia, Radu, & Simioni, 2016; Nomura, 2017) , so it may have the potential to surpass the detection of CTC in clinical studies.
| Future Prospects
Further optimization of the IMS-PS method seems to be required. First, using MicroBeads UltraPure and an MS Column, there is a tendency for nonspecific binding to subcellular components of non-target plasma particles. Although pretreatment of the microbeads with skim milk or an ECL-blocking agent reduced such binding, the development of magnetic bead with inherently low NSB would be useful. Second, we tentatively set the size gate at 0.5 µm to 2 µm, but this size range might miss a large number of exosomes (0.02-0.5 µm) and some apoptotic bodies (2-5 µm). Therefore, the clinically relevant EV size range needs to be determined in the future. Because staining of the EV phospholipid bilayer should show a good correlation with the surface membrane area, the size gate could be altered to smaller or larger ranges as long as the signal-tonoise ratio was reasonable.
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| EXPERIMENTAL PROCEDURES
| Cell culture
Two human epithelial tumor cell lines (OVCAR3 and A431) and a mouse colorectal tumor cell line (Colon-26) were obtained from the Cell Resource Center for Biomedical Research (Tohoku University, Japan). Cells were cultured in RPMI 1640 medium (FUJIFILM Wako Pure Chemical, Tokyo, Japan) containing 10% "regular" FBS (i.e., without depletion of animal EV; Thermo Fisher Scientific, MA, USA) and a penicillin/streptomycin cocktail (Roche Diagnostics, Basel, Swiss) in an incubator at 37°C under 5% CO 2 .
| Preparation of stock EV from culture supernatant
When cells in a 10-cm culture dish containing 10 ml of medium reached the late log phase of growth (60%-80% confluence), the medium was replaced with fresh medium that had been filtered through a membrane with 0.2 µm pores (Sartorius, Göttingen, DE). After 24 hr, the culture supernatant was collected and centrifuged in a conical tube at 500x g for 10 min to remove floating cells and large debris. Then, 8 ml of the 10 ml of supernatant was carefully transferred from the top to a new tube and was subsequently divided into aliquots for microtubes (1 ml/tube). The microtubes were centrifuged at 20,000x g for 60 min, after which the supernatant was removed and the precipitate in the tubes was frozen at −20°C until further use. For reconstitution, EV pellets were dissolved in 1 ml of PBS containing 2 mM EDTA (PBSE), unless otherwise noted.
| Preparation of plasma
Blood from healthy donors was collected into Vacutainer EDTA 2 K tubes (BD Biosciences, NJ, USA), and plasma was obtained by centrifugation of the blood samples at 3,000 rpm (1710x g) for 10 min. Measurements were performed on fresh plasma within one day, or the plasma was snap-frozen in liquid nitrogen and stored at −80°C until examination.
| Preparation of KIJY1N, a monoclonal antibody targeting human EpCAM
EpCAM is an epithelial tumor cell surface antigen that has an N-terminal EGF-like domain, a TY-domain and a cysteine-poor region. We previously established an mAb specifically targeting the cysteine-poor region of EpCAM (KIJY2) (Takao, Nagai, & Torii, 2013) . We also established KIJY1N (IgG1, κ), which is an mAb that reacts with the human EGF-like domain of EpCAM, by immunizing mice with human/mouse chimeric recombinant EpCAM (Supporting Information Figure S2) 
| Immunomagnetic separation of EV and phospholipid staining
We investigated positive separation of EV by using a manual MACS® system that included MACS Anti-Biotin MicroBeads UltraPure, an MS Column and a magnetic apparatus (Miltenyi Biotec, DE) . PBSE was employed as the dilution solution and the FCM sample elution buffer, while PBSE containing 0.05% Tween 20 (PBSET) was used for washing the MS Column. The standard protocol for positive MACS separation was followed. In addition, the fluorescent dye Polaric-500c6F (Goryo Chemical, Sapporo, Japan) was prepared as a 1 µM solution in PBSE for staining of the phospholipid bilayer of EV. In order to prepare KIJY1N-coated bead, Anti-Biotin MicroBeads UltraPure (100 µl) and biotinylated KIJY1N (25 µl of 1 µg/µl) were incubated together for 30 min at room temperature (RT). Then, the UltraPure-KIJY1N mixture was applied to the MS Column, washed twice with 500 µl of PBSE and eluted into 150 µl of PBSE with a plunger flush. The concentration of microbeads was evaluated by spectrophotometry (400 nm), and results for UltraPure-KIJY1N were normalized relative to those for a solution of uncoated Anti-Biotin MicroBeads UltraPure. The bead concentration of UltraPure-KIJY1N used was fourfold-diluted solution by compared with the original Anti-Biotin MicroBeads UltraPure. Accordingly, the uncoated UltraPure bead were diluted to the same concentration as UltraPure-KIJY1N, in some experiments (i.e., Figure 3) .
Immunoreactions between EV samples and microbeads were performed in microtubes with a reaction volume of 50 µl or 62.5 µl. The tubes were rotated horizontally in an orbital shaker (Biosan, Riga, Latvia) at 250 rpm for 30 min at RT. Positive separation was performed as follows by using a MACS MS Column. First, the column was pre-equilibrated with 500 µl of PBSE. The volume of each reaction mixture was increased to 500 µl by adding PBSE before application of samples to the column. After EV were captured in the magnetic field, the column was washed twice with 500 µl of PBSET. Next, 70 µl of Polaric-500c6F solution was added (MS Column void volume = 60 µl), the column outlet was sealed with a pushpin, and another 10 µl of dye solution was | Genes to Cells TAKAO eT Al.
overlaid on top to prevent drying. The optimum staining time was empirically determined and was fixed at 30 min, since incubation for 5-15 min resulted in weaker staining and staining showed a plateau with incubation for more than 20 min. After staining of EV, the column was washed three times with 500 µl of PBSET and once with 500 µl of PBSE. Then, the column was detached from the magnetic stand and the bound EV were eluted into an FCM sample tube with 500 µl of PBSE by gravity flow without plunger manipulation.
For the experiments on reduction in NSB shown in Figure  3 , skim milk (SM: FUJIFILM Wako Pure Chemical) or ECLblocking agent (GE Healthcare, Little Chalfont, UK) was dissolved in PBSE at 10%. Equal volumes of the blocking solution and uncoated UltraPure or UltraPure-KIJY1N bead solution were incubated together overnight at 4°C.
| FCM analysis and gate setup
A Cytomics FC 500 FCM analyser (Beckman Coulter, CA, USA) was used to obtain the data. EV size was determined by comparison with standard bead having a diameter of 0.5 µm, 1 µm and 2 µm (JSR Life Sciences, Tsukuba, Japan). The detector voltage for forward scatter (FS) was set so that the mean of the 1 µm bead was located at 10e1, while the size gate [S] was set between 0.5 and 2 µm (Supporting information, Figure  S1 ). The FL1 (505-545 nm) and FL2 (555-595 nm) channels were used for the detection of EV. Synthetic liposomes prepared from 1,2-dimyristoyl-sn-glycerol-3-phosphorylcholine (DMPC liposomes) (Ohba, Tsuchiya, Kumeta, & Ohki, 2005) were dissolved in PBSE, incubated with Polaric-500c6F, and used to set the FL1 and FL2 fluorescence detection channels (final concentrations: 20 µM DMPC liposomes and 0.1 µM Polaric-500c6F). The FC 500 settings for measurement of EV were a "low" flow rate, an acquisition time of "240 s" and a sample volume of 33.7 µl (CV=3%, n = 6).
EpCAM expression by the parental cell lines was also analysed by FCM after incubation of cells with a primary mAb (VU1D9, Santa Cruz Biotechnology, TX, USA) and a PE-conjugated polyclonal secondary antibody (ab97041, Abcam, Cambridge, UK). The FL2 channel was employed for the measurement of the PE histogram, and data were obtained with a "high" flow rate and an event limit of "20 000.".
